Use of bioanalytical assay to monitor plasma levels of perhexiline ( DrugBank: Perhexiline, MONITOR )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 58 | Hypertrophic cardiomyopathy | 1 |
58. Hypertrophic cardiomyopathy
Clinical trials : 119 / Drugs : 163 - (DrugBank : 45) / Drug target genes : 48 - Drug target pathways : 161
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02862600 (ClinicalTrials.gov) | August 1, 2016 | 8/8/2016 | Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure | A Phase 2, Multi-Center, Open-Label, Ascending Dose Study on the Efficacy, Safety and Tolerability of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure With Preserved Left Ventricular Function | Cardiomyopathy, Hypertrophic;Cardiomyopathy, Hypertrophic, Familial | Drug: Perhexiline;Device: Use of bioanalytical assay to monitor plasma levels of perhexiline | Heart Metabolics Limited | NULL | Terminated | 18 Years | N/A | All | 35 | Phase 2 | United States |